Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Healthy, regularly menstruating women were treated with the antiprogesterone RU 486, Mifepristone (Roussel-Uclaf, Romainville, France) during the follicular phase of the cycle. Three women were given 25 mg of RU 486 on days 1 to 14 of the cycle and five received 25 mg on days 1 to 21 of the cycle. Venous blood samples were collected three times per week during a control cycle and during one treatment cycle in each subject. Serum concentrations of estradiol (E2), progesterone (P), and RU 486 were determined by radioimmunoassays. No drug-related side effects and no spotting or bleeding during RU 486 treatment were observed. Menstrual bleeding was delayed by 8.7 +/- 3.8 days (mean +/- SD) after treatment over days 1 to 14 and by 12.6 +/- 3.2 days after treatment over days 1 to 21. During the treatment with RU 486, the serum concentrations of E2 remained low, indicating effective inhibition of folliculogenesis. After cessation of RU 486 treatment, serum E2 levels rose to similar values as in the control cycle, and subsequently serum P concentrations also reached ovulatory levels in six out of the eight volunteers. The results showed that the antiprogesterone RU 486 delayed folliculogenesis and luteinization even at low doses when given during the follicular phase of the menstrual cycle. It is speculated that this property of RU 486 could be utilized in the design of an estrogen-free combined oral contraceptives.
Luukkainen
T
T
Department of Medical Chemistry, University of Helsinki, Finland.
Heikinheimo
O
O
Haukkamaa
M
M
Lähteenmäki
P
P
D000328:Adult; D003280:Contraceptives, Oral, Synthetic / Q000097:blood / Q000494:pharmacology*; D003864:Depression, Chemical; D004958:Estradiol / Q000097:blood; D004963:Estrenes / Q000097:blood / Q000494:pharmacology*; D005260:Female; D005498:Follicular Phase / Q000187:drug effects; D006801:Humans; D015735:Mifepristone; D006080:Ovarian Follicle / Q000187:drug effects* / Q000502:physiology; D010060:Ovulation / Q000187:drug effects*; D011374:Progesterone / Q000037:antagonists & inhibitors* / Q000097:blood; D011863:Radioimmunoassay; D013997:Time Factors
D003280:Contraceptives, Oral, Synthetic; D004963:Estrenes; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol